Boomerang Medical announced that the first patients have been enrolled in its U.S. clinical trial assessing the use of nerve stimulation as potential treatment for Crohn’s disease and ulcerative colitis.
The FDA granted Boomerang Medical’s bioelectronic device its breakthrough device designation earlier this year for the treatment of inflammatory bowel disease through stimulation of the parasympathetic nervous system, which is intended to reduce inflammation.
The company reported that Kansas Gastroenterology, LLC, based in Wichita, Kansas, enrolled the first patient in the trial,